Doxycycline Injection [Doxy]
Preclinical
Doxycycline Injection [Doxy] is one of 6 therapeutic programs targeting Neurofibromatosis Type 2. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Neurofibromatosis Type 2
#DrugCompanyPhaseTrials
1Koselugo
AstraZenecaPhase 2
Selumetinib /m2
NNational Cancer Institute (NCI)
Phase 2
Luvometinib
SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
Serplulimab
Shanghai Henlius BiotechPhase 2
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Doxycycline Injection [Doxy]
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]